Anti-CD20 monoclonal antibodies: Beyond B-cells

Blood Reviews

Volumn 27, Issue 5, 2013, Pages 217-223

  Avivi, Irit ^a,b   Stroopinsky, Dina ^a   Katz, Tamar ^a,b  

^a Rambam Health Care Campus ^*  (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Anti CD20 monoclonal antibodies (MoAbs); Autoimmune diseases; B cells; Lymphoma; Rituximab; T cells

Indexed keywords

AME 133; CD20 ANTIBODY; OBINUTUZUMAB; OCRELIZUMAB; OFATUMUMAB; PRO 131921; RITUXIMAB; TOSITUMOMAB; UNCLASSIFIED DRUG; VELTUZUMAB;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNE DISEASE; B CELL LYMPHOMA; B LYMPHOCYTE; CELL EXPANSION; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG INDICATION; DRUG PROTEIN BINDING; DRUG SAFETY; EVENT FREE SURVIVAL; FOLLICULAR LYMPHOMA; GRAFT VERSUS HOST REACTION; HEPATITIS B; HUMAN; LARGE CELL LYMPHOMA; LYMPHOMA; MAINTENANCE THERAPY; MANTLE CELL LYMPHOMA; NONHODGKIN LYMPHOMA; NONHUMAN; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; VIRUS INFECTION;

ANTI-CD20 MONOCLONAL ANTIBODIES (MOABS); AUTOIMMUNE DISEASES; B-CELLS; LYMPHOMA; RITUXIMAB; T-CELLS;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; HUMANS; LYMPHOMA, B-CELL; T-LYMPHOCYTES;

EID: 84883553175     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2013.07.002     Document Type: Article

References (118)

1. Tedder T.F., Streuli M., Schlossman S.F., Saito H. Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes. Proc Natl Acad Sci U S A 1988, 85:208-212.
2. Uchida J., Lee Y., Hasegawa M., Liang Y., Bradney A., Oliver J.A., et al. Mouse CD20 expression and function. Int Immunol 2004, 16:119-129.
3. Beers S.A., Chan C.H., French R.R., Cragg M.S., Glennie M.J. CD20 as a target for therapeutic type I and II monoclonal antibodies. Semin Hematol 2010, 47:107-114.
4. O'Keefe T.L., Williams G.T., Davies S.L., Neuberger M.S. Mice carrying a CD20 gene disruption. Immunogenetics 1998, 48:125-132.
5. Reff M.E., Carner K., Chambers K.S., Chinn P.C., Leonard J.E., Raab R., et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994, 83:435-445.
6. Bello C., Sotomayor E.M. Monoclonal antibodies for B-cell lymphomas: rituximab and beyond. Hematology Am Soc Hematol Educ Program 2007, 233-242.
7. van Meerten T., Hagenbeek A. CD20-targeted therapy: a breakthrough in the treatment of non-Hodgkin's lymphoma. Neth J Med 2009, 67:251-259.
8. Lee S.C., Srivastava R.M., Lopez-Albaitero A., Ferrone S., Ferris R.L. Natural killer (NK): dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity. Immunol Res 2011, 50:248-254.
9. Hatjiharissi E., Xu L., Santos D.D., Hunter Z.R., Ciccarelli B.T., Verselis S., et al. Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158V/V and V/F polymorphism. Blood 2007, 110:2561-2564.
10. Srivastava S., Pelloso D., Feng H., Voiles L., Lewis D., Haskova Z., et al. Effects of interleukin-18 on natural killer cells: costimulation of activation through Fc receptors for immunoglobulin. Cancer Immunol Immunother 2013, 62:1073-1082.
11. Weng W.K., Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003, 21:3940-3947.
12. Ghesquieres H., Cartron G., Seymour J.F., Delfau-Larue M.H., Offner F., Soubeyran P., et al. Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms. Blood 2012, 120:2650-2657.
13. Grillo-Lopez A.J., White C.A., Dallaire B.K., Varns C.L., Shen C.D., Wei A., et al. Rituximab: the first monoclonal antibody approved for the treatment of lymphoma. Curr Pharm Biotechnol 2000, 1:1-9.
14. Janas E., Priest R., Wilde J.I., White J.H., Malhotra R. Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis. Clin Exp Immunol 2005, 139:439-446.
15. Deans J.P., Li H., Polyak M.J. CD20-mediated apoptosis: signalling through lipid rafts. Immunology 2002, 107:176-182.
16. George K.S., Wu S. Lipid raft: a floating island of death or survival. Toxicol Appl Pharmacol 2012, 259:311-319.
17. Zelenetz A.D. A clinical and scientific overview of tositumomab and iodine I 131 tositumomab. Semin Oncol 2003, 30:22-30.
18. Robak T. GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies. Curr Opin Investig Drugs 2009, 10:588-596.
19. Federico M., Luminari S., Dondi A., Tucci A., Vitolo U., Rigacci L., et al. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. J Clin Oncol 2013, 31:1506-1513.
20. Dotan E., Aggarwal C., Smith M.R. Impact of rituximab (rituxan) on the treatment of B-cell non-Hodgkin's lymphoma. P T 2010, 35:148-157.
21. Boye J., Elter T., Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol 2003, 14:520-535.
22. Press O.W., Palanca-Wessels M.C. Selection of first-line therapy for advanced follicular lymphoma. J Clin Oncol 2013, 31:1496-1498.
23. McLaughlin P., Grillo-Lopez A.J., Link B.K., Levy R., Czuczman M.S., Williams M.E., et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998, 16:2825-2833.
24. van Oers M.H., Klasa R., Marcus R.E., Wolf M., Kimby E., Gascoyne R.D., et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006, 108:3295-3301.
25. van Oers M.H., Van Glabbeke M., Giurgea L., Klasa R., Marcus R.E., Wolf M., et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol 2010, 28:2853-2858.
26. Salles G., Seymour J.F., Offner F., Lopez-Guillermo A., Belada D., Xerri L., et al. Rituximab maintenance for 2years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011, 377:42-51.
27. Lunning M.A., Vose J.M. Management of indolent lymphoma: where are we now and where are we going. Blood Rev 2012, 26:279-288.
28. Coiffier B., Lepage E., Briere J., Herbrecht R., Tilly H., Bouabdallah R., et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:235-242.
29. Pfreundschuh M., Kuhnt E., Trumper L., Osterborg A., Trneny M., Shepherd L., et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol 2011, 12:1013-1022.
30. Coiffier B., Thieblemont C., Van Den Neste E., Lepeu G., Plantier I., Castaigne S., et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 2010, 116:2040-2045.
31. Lenz G., Dreyling M., Hoster E., Wormann B., Duhrsen U., Metzner B., et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005, 23:1984-1992.
32. Griffiths R., Mikhael J., Gleeson M., Danese M., Dreyling M. Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma. Blood 2011, 118:4808-4816.
33. Robak T., Dmoszynska A., Solal-Celigny P., Warzocha K., Loscertales J., Catalano J., et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010, 28:1756-1765.
34. Hallek M. State-of-the-art treatment of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2009, 440-449.
35. Kluin-Nelemans H.C., Hoster E., Hermine O., Walewski J., Trneny M., Geisler C.H., et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med 2012, 367:520-531.
36. Barcellini W., Zanella A. Rituximab therapy for autoimmune haematological diseases. Eur J Intern Med 2011, 22:220-229.
37. Looney R.J. Treating human autoimmune disease by depleting B cells. Ann Rheum Dis 2002, 61:863-866.
38. Silverman G.J., Weisman S. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum 2003, 48:1484-1492.
39. Edwards J.C., Szczepanski L., Szechinski J., Filipowicz-Sosnowska A., Emery P., Close D.R., et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004, 350:2572-2581.
40. Cohen S.B., Emery P., Greenwald M.W., Dougados M., Furie R.A., Genovese M.C., et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006, 54:2793-2806.
41. Emery P., Fleischmann R., Filipowicz-Sosnowska A., Schechtman J., Szczepanski L., Kavanaugh A., et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006, 54:1390-1400.
42. Rastetter W., Molina A., White C.A. Rituximab: expanding role in therapy for lymphomas and autoimmune diseases. Annu Rev Med 2004, 55:477-503.
43. Taylor R.P., Lindorfer M.A. Drug insight: the mechanism of action of rituximab in autoimmune disease - the immune complex decoy hypothesis. Nat Clin Pract Rheumatol 2007, 3:86-95.
44. Stasi R. Rituximab in autoimmune hematologic diseases: not just a matter of B cells. Semin Hematol 2010, 47:170-179.
45. Wilk E., Witte T., Marquardt N., Horvath T., Kalippke K., Scholz K., et al. Depletion of functionally active CD20+ T cells by rituximab treatment. Arthritis Rheum 2009, 60:3563-3571.
46. Garvey B. Rituximab in the treatment of autoimmune haematological disorders. Br J Haematol 2008, 141:149-169.
47. Quartier P., Brethon B., Philippet P., Landman-Parker J., Le Deist F., Fischer A. Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet 2001, 358:1511-1513.
48. Cooper N., Stasi R., Cunningham-Rundles S., Feuerstein M.A., Leonard J.P., Amadori S., et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol 2004, 125:232-239.
49. Penalver F.J., Jimenez-Yuste V., Almagro M., Alvarez-Larran A., Rodriguez L., Casado M., et al. Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients. Ann Hematol 2006, 85:400-406.
50. Scheinberg M., Hamerschlak N., Kutner J.M., Ribeiro A.A., Ferreira E., Goldenberg J., et al. Rituximab in refractory autoimmune diseases: Brazilian experience with 29 patients (2002-2004). Clin Exp Rheumatol 2006, 24:65-69.
51. Penalver F.J., Alvarez-Larran A., Diez-Martin J.L., Gallur L., Jarque I., Caballero D., et al. Rituximab is an effective and safe therapeutic alternative in adults with refractory and severe autoimmune hemolytic anemia. Ann Hematol 2010, 89:1073-1080.
52. Zaja F., Vianelli N., Sperotto A., Patriarca F., Tani M., Marin L., et al. Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases. Leuk Lymphoma 2003, 44:1951-1955.
53. D'Arena G., Califano C., Annunziata M., Tartarone A., Capalbo S., Villani O., et al. Rituximab for warm-type idiopathic autoimmune hemolytic anemia: a retrospective study of 11 adult patients. Eur J Haematol 2007, 79:53-58.
54. Ahuja A., Anderson S.M., Khalil A., Shlomchik M.J. Maintenance of the plasma cell pool is independent of memory B cells. Proc Natl Acad Sci U S A 2008, 105:4802-4807.
55. Lund F.E., Randall T.D. Effector and regulatory B cells: modulators of CD4+ T cell immunity. Nat Rev Immunol 2010, 10:236-247.
56. Amagai M., Koch P.J., Nishikawa T., Stanley J.R. Pemphigus vulgaris antigen (desmoglein 3) is localized in the lower epidermis, the site of blister formation in patients. J Invest Dermatol 1996, 106:351-355.
57. Eming R., Nagel A., Wolff-Franke S., Podstawa E., Debus D., Hertl M. Rituximab exerts a dual effect in pemphigus vulgaris. J Invest Dermatol 2008, 128:2850-2858.
58. Stasi R., Cooper N., Del Poeta G., Stipa E., Laura Evangelista M., Abruzzese E., et al. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood 2008, 112:1147-1150.
59. Korngold R., Sprent J. Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T cells from marrow. J Exp Med 1978, 148:1687-1698.
60. Socie G. Chronic GVHD: B cells come of age. Blood 2011, 117:2086-2087.
61. Ratanatharathorn V., Nash R.A., Przepiorka D., Devine S.M., Klein J.L., Weisdorf D., et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998, 92:2303-2314.
62. Remberger M., Kumlien G., Aschan J., Barkholt L., Hentschke P., Ljungman P., et al. Risk factors for moderate-to-severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2002, 8:674-682.
63. Przepiorka D., Anderlini P., Saliba R., Cleary K., Mehra R., Khouri I., et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 2001, 98:1695-1700.
64. Ratanatharathorn V., Carson E., Reynolds C., Ayash L.J., Levine J., Yanik G., et al. Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease. Ann Intern Med 2000, 133:275-279.
65. Ratanatharathorn V., Ayash L., Reynolds C., Silver S., Reddy P., Becker M., et al. Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant 2003, 9:505-511.
66. Canninga-van Dijk M.R., van der Straaten H.M., Fijnheer R., Sanders C.J., van den Tweel J.G., Verdonck L.F. Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease. Blood 2004, 104:2603-2606.
67. Cutler C., Miklos D., Kim H.T., Treister N., Woo S.B., Bienfang D., et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 2006, 108:756-762.
68. Mohty M., Marchetti N., El-Cheikh J., Faucher C., Furst S., Blaise D. Rituximab as salvage therapy for refractory chronic GVHD. Bone Marrow Transplant 2008, 41:909-911.
69. Teshima T., Nagafuji K., Henzan H., Miyamura K., Takase K., Hidaka M., et al. Rituximab for the treatment of corticosteroid-refractory chronic graft-versus-host disease. Int J Hematol 2009, 90:253-260.
70. von Bonin M., Oelschlagel U., Radke J., Stewart M., Ehninger G., Bornhauser M., et al. Treatment of chronic steroid-refractory graft-versus-host disease with low-dose rituximab. Transplantation 2008, 86:875-879.
71. Zaja F., Bacigalupo A., Patriarca F., Stanzani M., Van Lint M.T., Fili C., et al. Treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplant 2007, 40:273-277.
72. Shlomchik W.D., Couzens M.S., Tang C.B., McNiff J., Robert M.E., Liu J., et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999, 285:412-415.
73. Ordemann R., Hutchinson R., Friedman J., Burakoff S.J., Reddy P., Duffner U., et al. Enhanced allostimulatory activity of host antigen-presenting cells in old mice intensifies acute graft-versus-host disease. J Clin Invest 2002, 109:1249-1256.
74. Quaranta S., Shulman H., Ahmed A., Shoenfeld Y., Peter J., McDonald G.B., et al. Autoantibodies in human chronic graft-versus-host disease after hematopoietic cell transplantation. Clin Immunol 1999, 91:106-116.
75. Patriarca F., Skert C., Sperotto A., Zaja F., Falleti E., Mestroni R., et al. The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery. Exp Hematol 2006, 34:389-396.
76. Wechalekar A., Cranfield T., Sinclair D., Ganzckowski M. Occurrence of autoantibodies in chronic graft vs. host disease after allogeneic stem cell transplantation. Clin Lab Haematol 2005, 27:247-249.
77. Cabanillas F., Liboy I., Pavia O., Rivera E. High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complication. Ann Oncol 2006, 17:1424-1427.
78. Aksoy S., Dizdar O., Hayran M., Harputluoglu H. Infectious complications of rituximab in patients with lymphoma during maintenance therapy: a systematic review and meta-analysis. Leuk Lymphoma 2009, 50:357-365.
79. Rafailidis P.I., Kakisi O.K., Vardakas K., Falagas M.E. Infectious complications of monoclonal antibodies used in cancer therapy: a systematic review of the evidence from randomized controlled trials. Cancer 2007, 109:2182-2189.
80. Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005, 31:456-473.
81. Gurcan H.M., Keskin D.B., Stern J.N., Nitzberg M.A., Shekhani H., Ahmed A.R. A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol 2009, 9:10-25.
82. Carson K.R., Evens A.M., Richey E.A., Habermann T.M., Focosi D., Seymour J.F., et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009, 113:4834-4840.
83. Koo Y.X., Tan D.S., Tan I.B., Tao M., Lim S.T. Hepatitis B virus reactivation in a patient with resolved hepatitis B virus infection receiving maintenance rituximab for malignant B-cell lymphoma. Ann Intern Med 2009, 150:655-656.
84. Tsutsumi Y., Kanamori H., Mori A., Tanaka J., Asaka M., Imamura M., et al. Reactivation of hepatitis B virus with rituximab. Expert Opin Drug Saf 2005, 4:599-608.
85. Chang H., Yeh H.C., Su Y.C., Lee M.H. Pneumocystis jiroveci pneumonia in patients with non-Hodgkin's lymphoma receiving chemotherapy containing rituximab. J Chin Med Assoc 2008, 71:579-582.
86. Kelesidis T., Daikos G., Boumpas D., Tsiodras S. Does rituximab increase the incidence of infectious complications? A narrative review. Int J Infect Dis 2011, 15:e2-e16.
87. Pfreundschuh M., Zeynalova S., Poeschel V., Haenel M., Schmitz N., Ho A.D., et al. Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL) after dose-dense rituximab: results of the DENSE-R-CHOP-14 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). J Clin Oncol 2008, 26:8508a.
88. Kamel S., O'Connor S., Lee N., Filshie R., Nandurkar H., Tam C.S. High incidence of Pneumocystis jirovecii pneumonia in patients receiving biweekly rituximab and cyclophosphamide, adriamycin, vincristine, and prednisone. Leuk Lymphoma 2010, 51:797-801.
89. Kolstad A., Holte H., Fossa A., Lauritzsen G.F., Gaustad P., Torfoss D. Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen. Haematologica 2007, 92:139-140.
90. Venhuizen A.C., Hustinx W.N., van Houte A.J., Veth G., van der Griend R. Three cases of Pneumocystis jirovecii pneumonia (PCP) during first-line treatment with rituximab in combination with CHOP-14 for aggressive B-cell non-Hodgkin's lymphoma. Eur J Haematol 2008, 80:275-276.
91. Pfreundschuh M., Zeynalova S., Poeschel V., Haenel M., Schmitz N., Hensel M., et al. Dose-dense rituximab improves outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL): results of the DENSE-R-CHOP-14 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood 2007, 110:789.
92. Aksoy S., Harputluoglu H., Kilickap S., Dede D.S., Dizdar O., Altundag K., et al. Rituximab-related viral infections in lymphoma patients. Leuk Lymphoma 2007, 48:1307-1312.
93. Evens A.M., Jovanovic B.D., Su Y.C., Raisch D.W., Ganger D., Belknap S.M., et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol 2011, 22:1170-1180.
94. Yeo W., Chan T.C., Leung N.W., Lam W.Y., Mo F.K., Chu M.T., et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009, 27:605-611.
95. Law J.K., Ho J.K., Hoskins P.J., Erb S.R., Steinbrecher U.P., Yoshida E.M. Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations. Leuk Lymphoma 2005, 46:1085-1089.
96. Tsutsumi Y., Tanaka J., Kawamura T., Miura T., Kanamori H., Obara S., et al. Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma. Ann Hematol 2004, 83:58-60.
97. Tuccori M., Focosi D., Maggi F., Cosottini M., Meini B., Lena F., et al. Progressive multifocal leukoencephalopathy: a report of three cases in HIV-negative patients with non-Hodgkin's lymphomas treated with rituximab. Ann Hematol 2010, 89:519-522.
98. Nishimoto T., Kuwana M. CD4(+)CD25(+)Foxp3(+) regulatory T cells in the pathophysiology of immune thrombocytopenia. Semin Hematol 2013, 50(Suppl. 1):S43-S49.
99. Stroopinsky D., Katz T., Rowe J.M., Melamed D., Avivi I. Rituximab-induced direct inhibition of T-cell activation. Cancer Immunol Immunother 2012, 61:1233-1241.
100. Sfikakis P.P., Souliotis V.L., Fragiadaki K.G., Moutsopoulos H.M., Boletis J.N., Theofilopoulos A.N. Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis. Clin Immunol 2007, 123:66-73.
101. Liossis S.N., Sfikakis P.P. Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells. Clin Immunol 2008, 127:280-285.
102. Hultin L.E., Hausner M.A., Hultin P.M., Giorgi J.V. CD20 (pan-B cell) antigen is expressed at a low level on a subpopulation of human T lymphocytes. Cytometry 1993, 14:196-204.
103. Eggleton P., Bremer E., Tarr J.M., de Bruyn M., Helfrich W., Kendall A., et al. Frequency of Th17 CD20+ cells in the peripheral blood of rheumatoid arthritis patients is higher compared to healthy subjects. Arthritis Res Ther 2011, 13:R208.
104. Forster F., Singla A., Arora S.K., Schmidt R.E., Jacobs R. CD20+ T cell numbers are decreased in untreated HIV-1 patients and recover after HAART. Immunol Lett 2012, 146:74-78.
105. Schweizer C., Reu F.J., Ho A.D., Hensel M. Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab. Ann Hematol 2007, 86:711-717.
106. Godeau B., Porcher R., Fain O., Lefrere F., Fenaux P., Cheze S., et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Blood 2008, 112:999-1004.
107. Taylor P.A., Friedman T.M., Korngold R., Noelle R.J., Blazar B.R. Tolerance induction of alloreactive T cells via ex vivo blockade of the CD40:CD40L costimulatory pathway results in the generation of a potent immune regulatory cell. Blood 2002, 99:4601-4609.
108. Hallek M., Fischer K., Humphrey K., Asikanius E., Busch R., Engelke A., et al. Obinutuzumab (GA101)+Chlorambucil (CLB) Or Rituximab (R)+CLB versus CLB alone in patients with chronic lymphocytic leukaemia (CLL) and pre-existing medical conditions (comorbidities): final stage 1 results of the CLL11 (BO21004) phase 3 trial. Hematol Oncol 2013, 31:114.
109. Jaeger U., Trneny M., Melzer H., Praxmarer M., Fridrik M.A., Nawarawong W., et al. Rituximab maintenance treatment versus observation in patients with aggressive B-cell lymphoma: results of the AGMT NHL13 trial. Hematol Oncol 2013, 31:136.
110. Garcia M., Bellosillo B., Sanchez-Gonzalez B., Garcia-Payarols F., Seoane A., Ferrer A.M., et al. Study of regulatory T-cells in patients with gastric malt lymphoma: influence on treatment response and outcome. PLoS One 2012, 7:e51681.
111. Vallerskog T., Gunnarsson I., Widhe M., Risselada A., Klareskog L., van Vollenhoven R., et al. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol 2007, 122:62-74.
112. Vigna-Perez M., Hernandez-Castro B., Paredes-Saharopulos O., Portales-Perez D., Baranda L., Abud-Mendoza C., et al. Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther 2006, 8:R83.
113. Muller R., Hunzelmann N., Baur V., Siebenhaar G., Wenzel E., Eming R., et al. Targeted immunotherapy with rituximab leads to a transient alteration of the IgG autoantibody profile in pemphigus vulgaris. Dermatol Res Pract 2010, 2010:321950.
114. Hauser S.L., Waubant E., Arnold D.L., Vollmer T., Antel J., Fox R.J., et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008, 358:676-688.
115. Monson N.L., Cravens P., Hussain R., Harp C.T., Cummings M., de Pilar Martin M., et al. Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitis. PLoS One 2011, 6:e17103.
116. Saadoun D., Rosenzwajg M., Landau D., Piette J.C., Klatzmann D., Cacoub P. Restoration of peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis. Blood 2008, 111:5334-5341.
117. Arai S., Sahaf B., Narasimhan B., Chen G.L., Jones C.D., Lowsky R., et al. Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. Blood 2012, 119:6145-6154.
118. van Dorp S., Resemann H., te Boome L., Pietersma F., van Baarle D., Gmelig-Meyling F., et al. The immunological phenotype of rituximab-sensitive chronic graft-versus-host disease: a phase II study. Haematologica 2011, 96:1380-1384.